Some drugs are more effective in certain cases than others, depending on the genetic variation, or mutation, of the cancer and the molecular make-up of the patient. There are about 90 known genetic mutations to which a treatment is available or the treatment is in late stage clinical trial. However, genomic testing in most countries, including Canada, is currently provided by a disparate variety of globally funded academic laboratories. The lack of centralized system has led to inequitable access, non-scalable solutions, and insufficient standardization and quality assurance. This initiative aims at establishing equitable access across Canada to our state-of-the-art cancer diagnostic test that surveys these 90 “actionable” mutations. Such a test will enable clinicians to prescribe available drug therapies based on the presence of the mutations and match the cancer and the patient with the highest likelihood of success in the shortest time possible, improving outcomes in a cost and time efficient manner.
In cancer care, understanding a patient’s personal genomic profile equips oncologists with valuable information to better diagnose, predict, treat and prevent disease.
The identification of the unique genetic and molecular make-up of a patient allows oncologists to dramatically improve cancer prevention, treatment, and monitoring. Contextual Genomics has developed a pipeline of DNA-based cancer tests, which will equip patients and their healthcare providers with valuable molecular information to determine the best course of treatment.
Next-generation sequencing (NGS), a versatile DNA sequencing method, has enabled researchers and diagnosticians the unique opportunity to view a patient’s genomic profile. Such data hold invaluable information that can assist in tailoring the most effective treatment for the patient. While NGS technology can unlock this information, it takes the expertise of the team interpreting this vast amount of data and well-designed bioinformatics tools to provide results that are meaningful to the clinician and to the patient.
A nationally distributed panel of tumor genetic profiles can reduce costs, improve quality, and increase availability regardless of where a patient lives. The panel contains 90 mutations, covering all current and phase III medicines in development.